CetrorelixPrescription fertility medicine
During IVF, timing matters as much as stimulating egg growth. Cetrorelix helps keep eggs from being released before the fertility team is ready to collect them.
What is Cetrorelix?
Cetrorelix is a GnRH antagonist used during assisted-reproduction treatment to prevent premature ovulation. Cetrotide is a subcutaneous medicinal preparation. 1 5
How it works
It blocks GnRH receptors and suppresses the luteinising-hormone surge that can trigger ovulation. Unlike a GnRH agonist, it does not begin with a stimulatory phase. 2 3
Effects studied
Preventing a premature LH surge
The EMA overview describes three main studies involving 814 women; cetrorelix prevented premature LH surges comparably to the treatments used for comparison. 1
Evidence: Clinical evidence for a specific role within fertility treatment.
Early comparison with triptorelin
An early randomised trial assigned 115 patients to cetrorelix and 39 to triptorelin. No LH surge occurred after cetrorelix administration, although that group had fewer eggs and embryos. 4
Evidence: One regimen-specific comparison; suppression of an LH surge and overall IVF success are different outcomes.
Ovarian hyperstimulation risk
A 2016 Cochrane review of 73 randomised trials involving 12,212 women found lower ovarian hyperstimulation syndrome risk with antagonist protocols: an assumed 11% risk with agonists corresponded to an estimated 6–9% with antagonists. There was no clear live-birth difference. 3
Evidence: Protocol-level evidence; it is not a cetrorelix-only estimate.
What does the evidence show?
Its role in ovarian stimulation is established. Whether a treatment leads to pregnancy or a live birth is a separate question, shaped by the whole IVF cycle.
Delaying ovulation until egg collection
An IVF cycle involves several medicines with different jobs. Some encourage follicles to develop; cetrorelix helps prevent an early release of eggs. That pause allows the clinic to plan egg collection. Cetrotide is the prescription medicine containing cetrorelix, given under the skin during a monitored fertility treatment. 5
This explains an apparent contradiction: a medicine that delays ovulation can be useful in treatment intended to achieve pregnancy. The aim is to coordinate the steps of assisted reproduction. 5
How it controls the signal
One link in the hormonal chain is GnRH, also called LHRH. It tells the pituitary gland to release hormones including luteinising hormone, or LH. A surge in LH can trigger ovulation. Cetrorelix blocks the receptor for that upstream signal. 2
This makes it a GnRH antagonist. It suppresses the signal directly, without the initial stimulation associated with GnRH agonists. Those two names sound similar, but describe different ways of controlling the same system. 3
What the clinical studies measured
In the three main studies summarised by the European Medicines Agency, involving 814 women, the key measure was prevention of an early LH surge. Cetrorelix performed similarly to the comparator medicines on that measure. Preventing that surge does not guarantee a pregnancy or birth. 1
One early randomised trial assigned 115 patients to a single-dose cetrorelix regimen and 39 to triptorelin. No LH surge occurred after cetrorelix administration, although that group had fewer eggs and embryos. This was a particular experimental regimen, not a schedule to copy from an article. 4
Does it make IVF safer or more successful?
A 2016 Cochrane review compared GnRH-antagonist protocols with long-course agonist protocols across 73 randomised trials involving 12,212 women. Antagonist protocols reduced ovarian hyperstimulation syndrome, or OHSS, a complication of ovarian stimulation. With an assumed OHSS risk of 11% in the agonist group, the review estimated 6–9% with antagonists. 3
The review found no clear difference in live birth: the estimate was compatible with both a modest decrease and a modest increase. This is evidence about treatment protocols across a drug class. It does not establish that cetrorelix alone improves every IVF outcome, and a 2016 review is not a complete account of current fertility practice. 3
Side effects that deserve attention
Local redness, itching or swelling can occur at the injection site. Severe allergic reactions are also possible; the product information describes supervision for the first administration and instructions on recognising a reaction. 1
OHSS remains a risk during ovarian stimulation even when an antagonist protocol is used. Worsening abdominal pain or swelling, vomiting or breathing difficulty during treatment needs prompt contact with the fertility team. The EU leaflet also lists pregnancy, breastfeeding, severe kidney disease and relevant allergies among reasons not to use Cetrotide. 2
Safety & status
Local redness, itching or swelling and severe allergic reactions are relevant risks. Product information describes supervision for the first administration. Pregnancy, breastfeeding, severe kidney disease and relevant allergies are listed contraindications. 1 2
Ovarian hyperstimulation syndrome can still occur during fertility treatment. Worsening abdominal pain or swelling, vomiting or breathing difficulty requires prompt contact with the fertility team. 2
Country and product status
Cetrotide, containing cetrorelix, is authorised in the EU for preventing premature ovulation during controlled ovarian stimulation followed by egg collection and assisted reproduction. This check covers the EU product; Swiss registration and availability have not been verified here.
Frequently asked questions
Does it stimulate egg production?
Its specific role is to prevent a premature LH surge during a broader stimulation protocol. 1
Does it eliminate ovarian hyperstimulation syndrome?
No. Antagonist protocols can reduce the risk relative to agonist protocols, but they do not eliminate it. 3
Sources
The checks completed for this entry are described below, including abstract-only checks. This is not a systematic review or complete prescribing information.
- EMA · Cetrotide: assessment overview and EU indication EU regulator · Overview, indication and pivotal-study summary checked 27 October 2026; not a new systematic review.
- EMA · Cetrotide product information and patient leaflet EU product information · Indexed leaflet passages checked for mechanism, restrictions and adverse effects; direct PDF request was rate-limited. Not a full prescribing-information review.
- Al-Inany et al. · GnRH antagonists for assisted reproductive technology (2016) Cochrane systematic review · Abstract and summary-of-results text checked. Protocol-level results, not a cetrorelix-only comparison.
- Olivennes et al. · Cetrorelix versus triptorelin during IVF (2000) Randomised trial · PubMed abstract checked; full paper not reviewed. Historical single-dose regimen.
- EMD Serono · Cetrotide patient leaflet (July 2025) US manufacturer patient information · Patient leaflet read for treatment role and administration context; EU restrictions are described separately above.
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The introduction above is independently written using the listed sources.